Sequoia-backed Chinese heart valve developer Venus Medtech gets funding from DCP Capital

Open heart surgery in progress. Photo: Pixabay

Venus Medtech, a heart valve developer in China, has secured an undisclosed amount of equity investment from China-focused private equity firm DCP Capital to further boost its research and development and the internationalisation of its existing heart valve products.

Continue reading this story with a subscription to DealStreetAsia.


Should your colleagues be reading this article too? Contact us for corporate subscriptions at